Purpose Erlotinib had proved efficacy in patients with advanced non-small cell lung cancer,
especially adenocarcinoma. The aim of this study was to evaluate the efficacy of erlotinib in …

7174 Background: Erlotinib is a potent HER1/EGFR TKI that is approved for the treatment as
a single agent in 2nd and 3rd line NSCLC. Several phase II studies have shown that …

Background: The effective targeted therapy for lung squamous cell carcinoma (SCC) is
needed. The epidermal growth factor receptor (EGFR) mutation rate is low in lung SCC. The …

Objective Erlotinib is a small-molecule inhibitor of EGFR tyrosine kinase, showing a
significant improvement of survival in non-small-cell lung cancer (NSCLC) after the failure of …

Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase
inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib …

To evaluate the efficacy and safety of erlotinib for non-small cell lung cancer (NSCLC), we
performed a population-based observational study. The study involved 307 patients treated …

Objective Erlotinib has demonstrated survival benefit in patients with not only
adenocarcinoma but also squamous cell carcinoma. Epidermal growth factor receptor …

Objective This study is to analyze the data of Chinese subpopulation in the Tarceva Lung
Cancer Survival Treatment Study (TRUST-China) which was a global Phase IV study …

Objective: To investigate the efficacy and adverse reaction of erlotinib as a single agent in
2nd and 3rd treatment of advanced non-small cell lung cancer (NSCLC) patients. Methods …

Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …